NCT07393659RecruitingPhase 3
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 181 (estimated)
- First submitted
- 30 Jan 2026
- Start date
- 21 Jul 2026
- Primary completion date
- 14 Sept 2032
- Lead sponsor
- ViiV Healthcare
- Diseases
- HIV
- NCT number
- NCT07393659
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 181
- From 21 Jul 2026 to the primary completion date, 14 Sept 2032
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Any reason that, in the opinion of the Investigator or Sponsor, precludes the participant's inclusion in the study.
Who the study is looking for
- Investigator confirmation of the participant's continued clinical benefit from the parent study intervention and the participant's completion of the protocol-defined treatment period in the parent study. The Investigator should ensure that the participant is still eligible for the parent study (i.e., have not met parent study discontinuation/ withdrawal criteria).
- Participants or legally authorized representative (LAR) who are willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in the applicable appendix and determined by the Investigator.
- Participant or LAR is able and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and this protocol. Where applicable, participants must provide written assent.
Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Durban | South Africa | Recruiting |
| - Coordinator of this site? Confirm its status | Gauteng | South Africa | Recruiting |
| - Coordinator of this site? Confirm its status | Johannesburg | South Africa | Recruiting |
| - Coordinator of this site? Confirm its status | Jouberton | South Africa | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.